These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29851174)

  • 1. Association between dipeptidyl peptidase-4 inhibitors and urinary tract infection in elderly patients: A retrospective cohort study.
    Imatoh T; Nishi T; Yasui M; Maeda T; Sai K; Saito Y; Une H; Babazono A
    Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):931-939. PubMed ID: 29851174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
    Komamine M; Kajiyama K; Ishiguro C; Uyama Y
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
    Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
    JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
    Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
    Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
    Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
    Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.
    Fadini GP; Saragoni S; Russo P; Degli Esposti L; Vigili de Kreutzenberg S; Melazzini M; Avogaro A;
    Diabetes Obes Metab; 2017 Oct; 19(10):1416-1424. PubMed ID: 28432754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
    Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
    Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea.
    Yang H; Choi E; Park E; Na E; Chung SY; Kim B; Han SY
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00910. PubMed ID: 35005849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
    Gokhale M; Buse JB; Gray CL; Pate V; Marquis MA; Stürmer T
    Diabetes Obes Metab; 2014 Dec; 16(12):1247-56. PubMed ID: 25109825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
    Yang BR; Cha SH; Lee KE; Kim JW; Lee J; Shin KH
    Osteoporos Int; 2021 Sep; 32(9):1705-1712. PubMed ID: 33594487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
    Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study.
    Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR
    Diabetes Res Clin Pract; 2018 Feb; 136():159-167. PubMed ID: 29258886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example.
    Dong YH; Wang SV; Gagne JJ; Wu LC; Chang CH
    Value Health; 2020 Feb; 23(2):217-226. PubMed ID: 32113627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
    J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
    Rebordosa C; Thomsen RW; Tave AK; Madsen M; Beachler DC; Martinez D; Garcia-Esteban R; Plana E; Tormos A; Farsani SF; Perez-Gutthann S; Pladevall-Vila M
    Diabetes Obes Metab; 2024 Apr; 26(4):1291-1304. PubMed ID: 38234181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study.
    Pradhan R; Yu OHY; Platt RW; Azoulay L
    BMJ Open Diabetes Res Care; 2023 Nov; 11(6):. PubMed ID: 37949470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
    Lee SG; Lee HJ; Yoon MS; Kim DH
    JAMA Dermatol; 2019 Feb; 155(2):172-177. PubMed ID: 30624566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.